SARS-CoV-2: The Virus, Its Biology and COVID-19 Disease-Counteracting Possibilities.
SARS-CoV-2
immunology
interferon pathway
safety issues
small molecules
vaccines
Journal
Frontiers in bioscience (Landmark edition)
ISSN: 2768-6698
Titre abrégé: Front Biosci (Landmark Ed)
Pays: Singapore
ID NLM: 101612996
Informations de publication
Date de publication:
31 10 2023
31 10 2023
Historique:
received:
25
04
2023
revised:
27
06
2023
accepted:
05
07
2023
medline:
6
11
2023
pubmed:
3
11
2023
entrez:
2
11
2023
Statut:
ppublish
Résumé
Since the end of 2019, the SARS-CoV-2 virus started to spread in different countries, leading to a world-wide pandemia, with today's infection numbers of more than 690 million and with a case fatality rate of more than 6.9 million. In addition, about 65 million patients suffer from post/long-Covid syndromes after having infections with the SARS-CoV-2 virus or variants thereof. This review highlights the biology of the virus, summarizes our knowledge of some of the viral mechanisms that counteract our immune responses, and finally also discusses the different vaccines and their specific safety profiles. Also, the possibility to fight this virus with recently available drugs (Veklury, Lagevrio and Paxlovid) will be discussed. All these data clearly argue that SARS-CoV-2 variants still exhibit a dangerous potential-although with a lower case fatality rate-and that vaccination in combination with drug intake upon infection may help to lower the risk of developing chronic or temporary autoimmune diseases.
Identifiants
pubmed: 37919074
pii: S2768-6701(23)00954-1
doi: 10.31083/j.fbl2810273
doi:
Substances chimiques
nirmatrelvir and ritonavir drug combination
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
273Informations de copyright
© 2023 The Author(s). Published by IMR Press.
Déclaration de conflit d'intérêts
The author declares no conflict of interest.